aTyr Pharma Inactive 10-Q2004 Q1 Quarterly report

Filed: 10 May 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: accretion, agricultural, amplify, annum, authoritative, Barthelemy, Baseball, Bear, begun, Benjamin, billable, biodefense, BioDiscovery, bioproduction, BioReliance, biotech, Bulkley, catastrophic, characterization, characterize, check, chemical, client, code, commence, Connecticut, construction, consume, death, detecting, detection, directly, disqualified, elucidate, energy, engineered, FAS, fee, filer, floating, FSP, Germany, Gibson, Glasgow, guidance, Haugland, Haven, Heidelberg, indemnity, isolate, Joseph, Karen, launched, leverage, LIBOR, Mallard, mammalian, mark, maximum, mechanism, Medicare, Modernization, monoclonal, Natick, native, noncash, notional, object, objectionable, objective, optimized, output, par, permanent, personal, physiological, point, possessing, postretirement, preclinical, prescription, presence, professional, purification, purify, ramp, reclassification, recover, reimbursable, reliability, repayment, retire, retirement, Richard, Rockville, Rodriguez, section, shorter, sponsor, Stirling, strength, subsidy, swap, swapped, telephone, tender, UBS, unbilled, Washington, welfare, Worchester, worker, Yesx, yield

Removed: adjusted, adjustment, Alabama, America, annually, approximated, Asia, Authority, buy, calculated, chief, Civil, cloning, closure, contesting, Department, derive, diagnostic, disclosed, Division, East, escrow, Ethrog, evaluated, expensed, expression, factor, gene, half, Huntsville, idle, ii, imputed, inception, inclusion, increasing, informed, Inspector, intent, Justice, labeled, leased, matter, meeting, merged, middle, nucleic, overfunded, paper, prepaid, produce, reevaluated, refund, registered, representing, Serva, South, statute, sublease, submitted, suite, tangible, termination, tolling, transfer, transitioned, VA, vivo

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

aTyr Pharma similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Gregory T. Lucier, Chief Executive Officer of Invitrogen Corporation (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

(1) the Quarterly Report on Form 10-Q of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.




Dated: May 6, 2004				/s/ GREGORY T. LUCIER

				Gregory T. Lucier
				Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Invitrogen and will be retained by Invitrogen and furnished to the Securities and Exchange Commission or its staff upon request.